Discover Novel Inhibitors with the Transcreener CD73 Assay
The Transcreener CD73 Assay measures adenosine (ADO) produced by ecto-5'-nucleotidase (also known as 5'-nucleotidase, NT5E, Cluster of Differentiation 73 or CD73). By measuring the production of ADO researchers can effectively determine the activity of the enzyme. The assay provides a powerful tool to screen entire compound libraries for CD73 modulators to help find new therapeutics for diseases such as cancer.
The assay uses a coupling enzyme that uses ADO produced by CD73 to produce the products AMP and ADP. ADP can then be measured using the trusted Transcreener ADP² Assay components. The kit comes complete with all the detection reagents required to measure activity. CD73 enzyme is not included in the inhibitor screening assay kit. Please contact us for questions related to acquiring the enzyme.
CD73 is an Important Messenger for Purinergic Signalling
Ectonucleotidases are plasma membrane-bound enzymes with externally-oriented active sites that metabolize nucleotides to nucleosides and are crucial for maintaining immune homeostasis. CD39, hydrolyzes ATP and ADP to AMP. AMP is further processed to Adenosine by CD73 leading to a significant impact on many disease states. Recent studies have shown a key role for Adenosine in immunosuppression in the tumor microenvironment, and ectonucleotidases are emerging as promising immuno-oncology targets. Learn more about targeting CD39 with the Transcreener AMP² Assay.